{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:00:55Z","timestamp":1793779255152,"version":"4.6.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["NK114P_14"],"award-info":[{"award-number":["NK114P_14"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["NK115P_07"],"award-info":[{"award-number":["NK115P_07"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["113-2314-B-037-107-MY3"],"award-info":[{"award-number":["113-2314-B-037-107-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["110-2314-B-037-068-MY3"],"award-info":[{"award-number":["110-2314-B-037-068-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019503","name":"Kaohsiung Municipal Ta-Tung Hospital","doi-asserted-by":"publisher","award":["114001"],"award-info":[{"award-number":["114001"]}],"id":[{"id":"10.13039\/100019503","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011645","name":"Kaohsiung Medical University Hospital","doi-asserted-by":"publisher","award":["KMUH114-4R15"],"award-info":[{"award-number":["KMUH114-4R15"]}],"id":[{"id":"10.13039\/501100011645","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.xkme.2026.101248","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:28:14Z","timestamp":1767860894000},"page":"101248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Sodium-Glucose Cotransporter-2 Inhibitors and Acute Kidney Injury Risk: A Systematic Review and Meta-Analysis of Randomized Trials"],"prefix":"10.1016","volume":"8","author":[{"given":"Yu-Cheng","family":"Chiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dao-Fu","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Wen","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6888-4138","authenticated-orcid":false,"given":"Hugo Y.-H.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.xkme.2026.101248_bib1","first-page":"1","article-title":"Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury","volume":"2","author":"John","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"9987","key":"10.1016\/j.xkme.2026.101248_bib2","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/S0140-6736(15)60126-X","article-title":"International Society of Nephrology's 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology","volume":"385","author":"Mehta","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.xkme.2026.101248_bib3","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1681\/ASN.2006070756","article-title":"Incidence and outcomes in acute kidney injury: a comprehensive population-based study","volume":"18","author":"Ali","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.xkme.2026.101248_bib4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2215\/CJN.00220605","article-title":"Epidemiology and outcomes of acute renal failure in hospitalized patients: a national survey","volume":"1","author":"Liangos","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.xkme.2026.101248_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-006497","article-title":"Long-term prognosis after acute kidney injury (AKI): what is the role of baseline kidney function and recovery? A systematic review","volume":"5","author":"Sawhney","year":"2015","journal-title":"BMJ Open"},{"issue":"22","key":"10.1016\/j.xkme.2026.101248_bib6","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJM199605303342207","article-title":"Acute renal failure","volume":"334","author":"Thadhani","year":"1996","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.xkme.2026.101248_bib7","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00134-015-3934-7","article-title":"Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study","volume":"41","author":"Hoste","year":"2015","journal-title":"Intensive Care Med"},{"issue":"1","key":"10.1016\/j.xkme.2026.101248_bib8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1056\/NEJMra1214243","article-title":"Acute kidney injury and chronic kidney disease as interconnected syndromes","volume":"371","author":"Chawla","year":"2014","journal-title":"N Engl J Med"},{"issue":"9843","key":"10.1016\/j.xkme.2026.101248_bib9","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S0140-6736(11)61454-2","article-title":"Acute kidney injury","volume":"380","author":"Bellomo","year":"2012","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.xkme.2026.101248_bib10","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.2215\/CJN.00710113","article-title":"World incidence of AKI: a meta-analysis","volume":"8","author":"Susantitaphong","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.xkme.2026.101248_bib11","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"22","key":"10.1016\/j.xkme.2026.101248_bib12","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.xkme.2026.101248_bib13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xkme.2026.101248_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000313738","article-title":"Pathophysiology of AKI: injury and normal and abnormal repair","volume":"165","author":"Bonventre","year":"2010","journal-title":"Contrib Nephrol"},{"issue":"1","key":"10.1016\/j.xkme.2026.101248_bib15","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1152\/ajpregu.00357.2011","article-title":"Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat","volume":"302","author":"Thomson","year":"2012","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"5","key":"10.1016\/j.xkme.2026.101248_bib16","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.xkme.2026.101248_bib17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"issue":"15","key":"10.1016\/j.xkme.2026.101248_bib18","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.xkme.2026.101248_bib19","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.xkme.2026.101248_bib20","first-page":"1881","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes. Reply","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.xkme.2026.101248_bib21","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.xkme.2026.101248_bib22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.xkme.2026.101248_bib23","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10741-020-10024-2","article-title":"Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors","volume":"26","author":"Margonato","year":"2021","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.xkme.2026.101248_bib24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ejphar.2017.05.019","article-title":"Characterization and comparison of SGLT2 inhibitors: part 3. Effects on diabetic complications in type 2 diabetic mice","volume":"809","author":"Tahara","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.xkme.2026.101248_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115629","article-title":"DPP-4i versus SGLT2i as modulators of PHD3\/HIF-2\u03b1 pathway in the diabetic kidney","volume":"167","author":"Samaan","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"10.1016\/j.xkme.2026.101248_bib26","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.5135","article-title":"SGLT2 inhibitors, functional capacity, and quality of life in patients with heart failure: a systematic review and meta-analysis","volume":"7","author":"Gao","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.xkme.2026.101248_bib27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12933-022-01476-x","article-title":"Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis","volume":"21","author":"Kaze","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"10.1016\/j.xkme.2026.101248_bib28","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1210\/clinem\/dgab274","article-title":"Clinical adverse events associated with sodium-glucose cotransporter 2 inhibitors: a meta-analysis involving 10 randomized clinical trials and 71 553 individuals","volume":"106","author":"Lin","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.xkme.2026.101248_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002983","article-title":"Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a systematic review and meta-analysis","volume":"16","author":"Menne","year":"2019","journal-title":"PLoS Med"},{"issue":"4","key":"10.1016\/j.xkme.2026.101248_bib30","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.xkme.2026.101248_bib31","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526000099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526000099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T22:21:28Z","timestamp":1784067688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059526000099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2590059526000099"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101248","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium-Glucose Cotransporter-2 Inhibitors and Acute Kidney Injury Risk: A Systematic Review and Meta-Analysis of Randomized Trials","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101248","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101248"}}